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Abstract
Study Objective: Girls with Turner syndrome with Y-chromosome material (TS + Y) are
assumed to have nonfunctional gonads with increased tumor risk, therefore prophylactic
gonadectomy is recommended at diagnosis. In this study we aimed to determine rates of
spontaneous thelarche (ST) and spontaneous menarche (SM), and prevalence of gonadal tumor
and malignancy in girls with TS + Y, to further inform discussions about gonadectomy.
Design: Retrospective review of clinical and pathology data.
Setting: Multicenter study involving 4 United States children’s hospitals.
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Participants: Patients included those with a genetically proven diagnosis of TS + Y and
phenotypically female genitourinary exam.
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Interventions: Demographic characteristics, pubertal development, and gonadal pathology data
were abstracted from clinical records. Data for ST were analyzed for patients aged 13 years and
older and SM for patients older than 15 years.
Main Outcome Measures: ST, SM, prevalence of gonadal tumor, and malignancy.
Results: Forty-four patients met inclusion criteria. Nineteen patients were 13 years or older; 8/19
(42%) had ST and reached Tanner stages 2–4 and 2 (11%) had normal ovarian pathology. Nineteen
patients were 15 years or older; 2/19 (11%) had SM. Thirty-seven patients underwent
gonadectomy; 35 had available pathology results. Gonadoblastoma was identified in 35/7 patients
(19%), 1 in situ germ cell neoplasia, and 1 dysgerminoma (3%). One patient with bilateral
gonadoblastoma had ST and SM.
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Conclusion: In this multicenter cohort, 42% of girls with TS + Y entered puberty spontaneously
and 11% had SM, supportive of gonadal function. Risk of tumor was similar to previous reports.
To achieve informed decision-making, discussions about gonadectomy should incorporate
potential for gonadal function and tumor risk.
Keywords
Turner syndrome with Y chromosome; Turner syndrome; Sex chromosome DSD; Infertility;
Ovarian insufficiency; Gonadal dysgenesis; Gonadoblastoma

Introduction

Author Manuscript

Turner syndrome (TS) is a condition characterized by female phenotype and 45,X genotype
with or without identifiable mosaicism. TS is variable in presentation and severity. The most
common features of TS are short stature and premature ovarian insufficiency. Approximately
12% of girls with TS also have Y-chromosome material (TS + Y).1 Like other girls with TS,
their genitalia is phenotypically female. Individuals with a 45,X/46,XY karyotype who have
any degree of virilization (ie, atypical or male-typical genitalia) are not considered to have
TS.
Girls with TS + Y constitute a unique category of TS because of their risk of
gonadoblastoma, a premalignant germ cell tumor with risk of malignant transformation.
Reported rates of gonadoblastoma range widely from 2% to 50% and reported rates of
malignant transformation are low, from 1% to 12%.2–13 Although gonadoblastoma has been
identified in infancy, malignant transformation does not typically occur until the second
decade of life, although there is one report in a girl with TS + Y as young as 6 years old.13

Author Manuscript

In 2016, the International Turner Syndrome Consensus Group published clinical practice
guidelines for TS, recommending that girls with TS + Y undergo gonadectomy at the time of
diagnosis, but acknowledged this is on the basis of a low level of evidence and further
research is needed.14 The recommendation for gonadectomy at the time of diagnosis aims to
prevent malignancy and is on the basis of an assumption that the gonads have little potential
for hormone production or fertility.2,3 For an individual or family, accurate information
about potential future hormone function and fertility is one important factor that might
inform if and when to perform gonadectomy. Supporting the need for accurate information
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about ovarian function in TS + Y, infertility has been reported as the most significant
stressor to patients with TS.15 Infertility and abnormal pubertal development are also the
most commonly cited reasons for couples electing termination of a pregnancy confirmed to
have TS.16

Author Manuscript

Little evidence is available about hormone function and fertility potential in women with TS
+ Y. To our knowledge, only 3 case reports of women with TS + Y are available in the
literature documenting spontaneous pregnancy and subsequent live birth, which shows that
some women with TS + Y have gonadal function.15–18 Incomplete understanding of
potential future ovarian function and fertility for girls with TS + Y impairs counseling and
informed decision-making, particularly surrounding gonadectomy. To address this
knowledge gap in care and improve the informed decision-making process, a retrospective
multicenter study was conducted to assess the prevalence of spontaneous thelarche (ST),
spontaneous menarche (SM), and occurrence of gonadoblastoma and malignant
transformation among girls with TS + Y.

Materials and Methods

Author Manuscript

Four children’s hospitals participated in this retrospective chart review in which clinical
characteristics and gonadal pathology from patients with TS + Y were assessed. Each
hospital’s institutional review board approved the study. Participants were identified at each
site with the use of the ninth revision of the International Classification of Diseases codes
associated with TS + Y. Search terms included: TS, TS with mosaicism, TS with X/XY
mosaicism, mosaic, mosaic TS, history of TS, Ullrich-TS, XY-TS, Male TS, X Turner’s
syndrome, X/XY Turner mosaicism, and other variants of TS. Inclusion criteria for this
study were a diagnosis of TS with presence of Y chromosome material (genetic testing for
karyotype and/or fluorescence in situ hybridization [FISH] analysis) along with
documentation of a phenotypically female external genitourinary exam.
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The study cohort consisted of 44 individuals. Phenotypic data were gathered retrospectively
from the electronic medical record using manual extraction by reviewers at each study site.
The following data elements were collected: demographic characteristics, karyotype and
FISH results for all tested tissues, Tanner staging by an endocrinologist, history and age of
ST and SM, pelvic ultrasound (US) results before and after gonadectomy, age and indication
for gonadectomy, gross pathology and histology of gonadal tissue, follow-up after
gonadectomy, and any attempts at fertility preservation or pregnancy. ST was defined as
breast development before exposure to exogenous estrogen and SM as menses before
exposure to exogenous estrogen. Pubertal failure was defined as lack of ST by 13 years and
lack of SM by 15 years, on the basis of commonly accepted normal ranges for ST and SM in
women.19,20 All deidentified data were sent to the lead site for statistical analysis.
Data were stored and analyzed in Research Electronic Data Capture software hosted at
Northwestern University. Statistical analysis within Research Electronic Data Capture
included descriptive statistics to summarize demographic characteristics and clinical features
including karyotype information, US findings, rates of ST and SM, and pathology data.
Means with SD are presented as appropriate.
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Results
Data from 44 girls with TS + Y were included in this analysis and their characteristics are
shown in Table 1. Peripheral blood karyotype identified Y material in all patients.
Additionally, 16 had Y chromosome material identified in peripheral blood according to
FISH analysis, 5 had Y chromosome material identified on gonadal karyotype, and 1 had Y
chromosome material identified on fibroblast karyotype.
Gonadectomy and Malignant Transformation
Abdominal US before gonadectomy was performed in 27 patients. A prepubertal uterus was
seen in 25 (93%) patients and 2 had no uterus visualized. Ovaries were visualized bilaterally
in 10 patients (27%) and unilaterally in 3 (11%). Two patients (7%) with ST had no ovaries
visualized on US. No masses were noted on US in any patients.

Author Manuscript

Thirty-six of the 44 patients (81%) underwent gonadectomy at an average age of 10.8 years
(age range, 0.8–18 years) and pathology results were available for all 36 patients. Pathology
reports confirmed 9 (25%) patients had germ cell tumors (Table 2). Of these patients, 7
(19%; 95% confidence interval, 8%−35%; age range, 6–216 months at diagnosis) had
gonadoblastoma (4 unilateral, 3 bilateral), 1 had dysgerminoma (3%; 95% confidence
interval, 0.1%−14%; 144 months of age at diagnosis), and 1 had nonspecific in situ
neoplasia. Of those with abnormal gonadal pathology who had preoperative US (n = 7), the
US examinations either showed normal gonads or gonads were unable to be visualized (no
tumor was identified). One patient (age 21 years) had gonads evaluated for possible fertility
preservation, and no germ cells were identified.
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Spontaneous Thelarche
In this cohort, 19 of the 44 patients were older than 13 years at the time of gonadectomy or
had not undergone gonadectomy. Eight of the 19 (42%) had ST; details are shown in Table 3.
Age of thelarche was only available in 4 patients, so average age could not be accurately
determined. Tanner staging was available in 7 of these patients (35%): 2 patients achieved
Tanner 2 breast tissue, 4 patients achieved Tanner 3, and 1 patient achieved Tanner 4; the
remainder were not recorded.
SM
In this cohort, 19 of the 44 patients were 15 years or older at the time of gonadectomy or had
not undergone gonadectomy. Two reported spontaneous menses before gonadectomy (11%).

Author Manuscript

Discussion
Current guidelines recommend that individuals with TS + Y undergo gonadectomy at the
time of diagnosis because of risk of developing gonadal tumor and potential malignant
transformation. There is limited information characterizing timing of malignant
transformation, ovarian function, and fertility potential among patients with TS + Y. In this
study we aimed to enrich the body of evidence informing gonadectomy in TS + Y to aid
counseling and informed decision-making. It is the first study, to our knowledge, to
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specifically assess rates of ST and SM in patients with TS + Y so data on ovarian function
and fertility potential might be better factored into consideration of gonadectomy.
In this cohort of girls with TS + Y at pubertal ages, 42% had ST and 11% had SM. Although
estrogen can arise from peripheral aromatization in adipose tissue and lead to some breast
development, more advanced stages of breast development and menarche suggests estrogen
exposure from ovarian function. Whether this ovarian function translates to fertility potential
is unknown. Borgstrom et al reported that a history of ST and SM in adult women with TS is
associated with fertility potential, and that these individuals would be candidates for fertility
preservation.21 In addition, several case reports of pregnancy in women with TS + Y have
been published. Thus, thelarche, menarche, and fertility are all possible in girls with TS + Y.
This raises the question of whether recommendations about gonadectomy at time of
diagnosis for girls with TS + Y should be reconsidered.

Author Manuscript
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In evaluating recommendations for gonadectomy, understanding the risk of developing a
malignancy is crucial. In the present study, the rate of gonadoblastoma was 19%, similar to
previous reports. Gonadoblastoma is a premalignant lesion with the potential for malignant
transformation, but if and when it will undergo malignant transformation is not known. The
only established risk factors for malignant transformation are older age and intra-abdominal
location.22 There is a paucity of data about mortality from gonadal malignancy in TS + Y,
but in our review of the literature, no deaths were reported.23 In our study, the rate of
malignancy was 3%, with confidence interval up to 8%, also similar to previous reports.
Complete understanding of timing and progression of malignant transformation is limited
because most patients have gonadectomy at early ages and thus accurate risk assessment
remains difficult to determine. Monitoring for tumor using imaging is not reliable, further
complicating decisions about gonadectomy. Previous studies in differences/disorders of sex
development (DSD) have shown that imaging using US or magnetic resonance does not rule
out a neoplasms in patients with gonadal dysgenesis.24 Similarly, in our study, no evidence
of dysgerminoma was seen on US before diagnosis.

Author Manuscript

Weighing the potential for ovarian function and fertility vs the risk of gonadal malignancy is
complicated. It is useful to consider the debate about gonadectomy in DSD. Gonadectomy in
DSD in the pediatric population has become increasingly controversial because of the
potential benefits of endogenous hormone production, preservation of possible future
fertility, and ethical concerns. One ethical consideration is assent and autonomy for
decisions about reproductive organs. Some also argue that gonadectomy itself results in a
physical and emotional loss for patients.25 Other ethical issues include creating false hope
for fertility potential and transmission of a genetic condition to offspring.13,17,25 For the
latter concern, some ethicists argue that individuals have the responsibility to produce the
“best” offspring they can whereas others assert that this is a eugenic view and individuals
with medical problems can lead happy, valuable lives.25 Increasingly, risk of malignancy in
DSD can be stratified and recommendations about timing of gonadectomy have shifted to
account for lesser or greater risk.26–28 In complete androgen insensitivity syndrome, for
example, the prepubertal risk of malignancy is thought to be low, at approximately 2%.
Thus, to preserve hormone function and autonomous decision-making, it is recommended to
allow these individuals to undergo spontaneous puberty via aromatization of androgens and
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then to perform gonadectomy postpubertally or to biopsy and follow.28 In TS + Y the risk of
malignancy might be higher, but if girls have a 42% chance of ST, and 11% chance of SM
and potential fertility, we should consider an open and thoughtful discussion about all of
these factors in making a decision about gonadectomy. On the basis of the existing literature,
which suggests that infertility is one of the most significant concerns among families,15
some patients and families might place greater importance on potential ovarian function,
whereas others might prioritize avoidance of malignancy risk. Although further research on
fertility preservation for individuals with TS + Y is needed to fully incorporate it into the
decision-making process about gonadectomy, if proceeding with gonadectomy, fertility
preservation options should be addressed.

Author Manuscript

Although this was a relatively large sample compared with previous studies, there are
important limitations to consider. The patient cohort remains small because TS + Y is a
relatively rare condition. Most patients underwent gonadectomy before pubertal age,
limiting assessment of gonadal function as well as timing of malignant transformation.
Additionally, this was a retrospective study, limiting the ability to obtain further information
when medical records were incomplete. There was also no biochemical assessment of the
pituitary-gonadal axis to confirm that ST and SM were caused by pubertal rises in
gonadotropin and estradiol levels. In discussion of fertility potential, in this study we
extrapolated ovarian function to the potential for fertility, but it is not known whether this
will prove to be an accurate indicator. Additionally, data on anti-Müllerian hormone levels
were not collected in this study, a measurement that might provide some additional data
about ovarian reserve. Data including biochemical assessment and postpubertal evaluation of
fertility should be assessed in the future to broaden understanding of gonadal function in TS
+ Y.

Author Manuscript
Author Manuscript

On the basis of our data, we suggest that multidisciplinary teams present current guidelines
about gonadal management at the time of diagnosis. In addition, however, we suggest that
they also discuss the complexities and unknown factors regarding this recommendation. On
the basis of existing data, families can be reassured that this is rarely a decision that requires
urgent action. In addressing tumor risk, it is important to discuss estimated risk and
challenges in reliable monitoring, but also that malignancy is extremely rare before the
second decade of life and that mortality from such cancer in TS + Y has not been reported.
Patients and families should be counseled that: (1) spontaneous pubertal development and
continuing ovarian function might be difficult to predict, particularly at young ages; and (2)
spontaneous fertility has been reported, although very rarely, and that there are no clear data
about likelihood of fertility potential. Potential contributing data, including biochemical
assessment and imaging, might be useful to provide additional guidance. An individual’s
current ovarian function might be assessed via gonadotropin levels. Reliable biochemical
assessment of ovarian reserve in the pediatric population is not proven, but it is possible that
anti-Müllerian hormone levels are predictive.21 After presenting these considerations,
patients and families should weigh the factors that are most important to them and make an
informed decision with the support of a multidisciplinary team.
To our knowledge, this study is the first to characterize rates of ST and SM among a large
and diverse cohort of girls with TS + Y, and showed that nearly half the girls with TS + Y
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have signs of estrogen exposure, which might indicate ovarian function. It also provides
supporting evidence for the published frequency of gonadoblastoma occurrence and
malignancy. Although future studies are needed to refine our understanding of ovarian
function in this population, the data can be used to counsel about potential ovarian function
and malignancy risk to allow for informed, individualized decision-making for gonadectomy
in girls with TS + Y.
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Patient Characteristics (N = 44)
Variable
Age at diagnosis (n = 41)

Value
9.5 [0–17.5] years

Race/ethnicity
White

16 (36)

Hispanic/Latino

7 (16)

Black/African American

1 (2)

Asian

2 (5)

Unknown

18 (40)

Peripheral blood karyotype
45,X/46,XY

26 (59)

Other karyotype*

18 (41)

Author Manuscript

†

Age at gonadectomy (n = 31)

10.8 [0.3–18.0] years

†

Gonadal pathology (n = 36)
Bilateral streak gonad

22 (61)

Unilateral gonadoblastoma, unilateral streak gonad

4 (11)

Bilateral gonadoblastoma

3 (8)

Unilateral streak gonad, unilateral normal ovary

2 (6)

Unilateral dysgerminoma, unilateral streak gonad

‡

1 (3)
4 (11)

Other

Data are presented as n (%) or median [range].

*

Author Manuscript

Other karyotypes include: 45,X mosaicism with 1 or more of the following: isodicentric Y chromosome; derivative X or Y chromosome resulting
from sex chromosome translocation; ring sex chromosome; 47,XYY; 46,XY/47,XYY; and 47,XY+21.

†

Thirty-seven patients had gonadectomy, age data were available for 31 patients, and pathology results were available for 36 patients.

‡

Other pathology results include: bilateral streak gonad with unilateral testicular tissue; dysgenetic gonad with in situ germ cell neoplasia; gonads
with Leydig cell elements; and per report, “normal.”

Author Manuscript
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15
14
Unknown
Unknown
Unknown
12
N/A

45,X/46,XY

45,X/46,XY

45,X/46,XY

45,X/46,XY

45,X [15]/46,X,idic(Y) (q11.1)[5]

45,X/46,XY

45,X[4]/46,X,idic(Y) (q11.2)[46]

–

12

–

–

17

–

–

–

Age at SM, years

N/A, not applicable; SM, spontaneous menarche; ST, spontaneous thelarche.

11

46,X,der(X)t(X; Y) (q8; p11.23)

Age at ST, years

Author Manuscript

Peripheral Blood Karyotype

Bilateral gonads with Leydig cell elements

Bilateral streak gonad

Bilateral streak gonad

Normal ovary

Bilateral gonadoblastoma

Bilateral streak gonads

Unilateral streak gonad, unilateral normal ovary

Bilateral streak gonad

Gonadal Pathology

Other Pathology

–

Wolffian and Müllerian structures

–

–

–

Adrenal rest

Wolffian structures

Adrenal rest

Author Manuscript

Patients with ST and SM

Author Manuscript

Table 2
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–
45,X/46,XY
–
45,X/47,XYY

45,X/46,XY

45,X/46,XY

45,X/46,XY

45,X/46,X, idic(Y) (q11.23)

Right gonad: 45,X[17]/
47,XYY[2]/46,XY[1] Left
gonad: 45, X [18]/46,XY[2]

1

N/A

N/A

12

11

10

2

1

16

Age at Gonadectomy,
years

Dysgenetic gonads with in situ germ cell
neoplasia

Streak gonad, unilateral gonadoblastoma

Streak gonad, unilateral gonadoblastoma

Bilateral gonadoblastoma

Streak gonad, unilateral gonadoblastoma

Streak gonad, unilateral gonadoblastoma

Bilateral gonadoblastoma

Bilateral gonadoblastoma

Streak gonad, dysgerminoma

Gonadal Pathology

Copies of SRY in this individual differed in peripheral blood and gonadal tissue. Gonadal tissue was mosaic for 3 cell lines with 0, 1, and 2 copies of SRY.

*

N/A, not applicable.

45,X/46,XY

Patients with in situ germ cell neoplasia

–

–

45,X/46,XY

46,X,idic(Y) (q11.23)/46,X,r(Y) (p11.3q11.23)/
45,X

–

–

45,X/46X,idic(Y) (p11.3)

Patients with gonadoblastoma

45,X/46,XY

Patients with dysgerminoma

Gonadal Karyotype

Author Manuscript

Peripheral Blood Karyotype

Author Manuscript

Patients with Gonadal Neoplasia

Gonads not visualized

N/A

N/A

N/A

Gonads not visualized

Normal gonads

Gonads not visualized

Normal gonads

Gonads not visualized

Ultrasound Result

2, 2/1*

2

2

1

1

1

1

2

1

Copies of SRY

Author Manuscript

Table 3
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